Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-935 PET Study in Healthy Subjects
NCT02497235Phase 1Completed
- Sponsor
- Takeda
- Start
- Jul 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of soticlestat in epilepsy, sponsored by Takeda. Primary endpoint: Cholesterol 24S-Hydroxylase (CH24H) Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 24 hours. Started Jul 2015; status: completed.
02
Drugs
soticlestat
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT02497235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02497235.